Imunexus' technology facilitates rapid, cost-effective, lower risk, generation of effective therapeutics by converting existing monoclonal antibodies into multispecifics with additional therapeutic utility.
Our technology will generate a number of potential products for the treatment of a number of cancers, autoimmune and other serious diseases.